Avelumab Program Rollover Study

You may be able to join if

• Participants are ≥ 18 years of age at the time of signing the informed consent.
• Participants are under enrollment in an avelumab clinical study under the sponsorship of EMD Serono Research & Development Institute, Inc. / Merck KGaA / Merck Serono Co., Ltd (Japan).
• Participants currently enrolled in an avelumab parent study where the primary/main analysis has been completed and who are: • Currently on active avelumab treatment in any parent study, regardless of indication, OR • In long-term survival follow-up after treatment (participants in Non-Small Cell Lung Cancer [NSCLC], Renal Cell Carcinoma [RCC], Urothelial Carcinoma [UC], and ovarian cancer indications only), OR • Who experienced CR in the parent study and discontinued avelumab treatment according to the parent study protocol.
• Participants are male or female. Participants on active treatment must agree to continue to use highly effective contraception (ie, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists (Note: The effects of the study intervention on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Appendix 3 (Contraception) or as stipulated in national or local guidelines. Highly effective contraception must be used 28 days prior to the first study intervention administration, for the duration of study intervention, and at least for 60 days after stopping study intervention. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the treating physician should be informed immediately).
• Participants can give signed informed consent, as indicated in Appendix 2 (Study Governance), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.